Osteoporosis and vascular disease affect large numbers of aging individuals, and there is increasing evidence that the two disorders are closely related. Both animal and human data indicate that osteoporosis is associated with vascular disease and calcification. Moreover, the process of vascular calcification appears to involve pathways very similar to those utilized during normal bone formation. Circulating endothelial progenitor cells (EPCs) are now increasingly recognized as playing an important role in initiating vascular repair in response to endothelial injury. Our recent demonstration that patients with vascular disease have a 5- to 8-fold greater percentage of EPCs expressing an osteogenic phenotype, as assessed by staining for the bone- related protein, osteocalcin (OCN), has led us to propose the overall novel concept that expression of an osteogenic phenotype by circulating EPCs may explain, at least in part, the increase in vascular calcification that occurs with aging and in the setting of atherosclerosis. In the present, multi-disciplinary proposal utilizing the multiple PI mechanism (Dr. Lerman [Vascular Disease, Cardiology] and Dr. Khosla [Bone Metabolism, Endocrinology]), along with the help of an expert in Vascular Biology (Dr. Simari) as Co-Investigator, we will test this hypothesis within the context of our three Specific Aims:
Aim 1 : Using purified EPCs from patients undergoing cardiac catheterization, test the hypotheses that, as compared to normal control subjects, circulating EPCs from patients with established CAD express an osteogenic "transcriptosome" (i.e., multiple bone-related genes/pathways) and have an increased ability to form mineralized nodules and/or enhance mineralization of vascular smooth muscle cells in vitro.
Aim 2 : In in vivo studies using murine models, test the hypotheses that that local delivery of EPCs expressing an osteogenic phenotype (defined by staining for the osteoblastic marker, AP), as compared to EPCs negative for AP staining, leads to increases in both subcutaneous bone formation (Aim 2a) and vascular calcification (Aim 2b).
and Aim 3 :In clinical studies in patients with non-obstructive CAD undergoing coronary cardiac catheterization, test the hypotheses that the expression of osteogenic/mesenchymal markers (OCN, AP, Stro-1) by systemically circulating EPCs correlates with early atherosclerosis (as defined by endothelial dysfunction) and with vascular calcification (as assessed by the sensitive method of intravascular ultrasound [IVUS]) (Aim 3a), and that these osteogenic EPCs are being consumed by the coronary circulation (Aim 3b). The proposed studies thus test novel hypotheses using a multidisciplinary approach. Moreover, the results of these studies are likely to have significant implications for our understanding of the mechanisms initiating vascular calcification as well as the increasing pathophysiological link between the vasculature and bone metabolism.

Public Health Relevance

Aging is associated with osteoporosis and with vascular (blood vessel) disease. In addition, patients with osteoporosis (who have reduced bone) have an increased risk of vascular calcification, which is associated with formation of bone-like structures in blood vessels and with heart attacks and strokes. The proposed work focuses on the role of circulating cells which likely arise from the bone marrow in initiating vascular calcification as opposed to normal repair. These studies should help us better understand how vascular calcification occurs, and perhaps ways of modifying the process into a more normal repair process, which would have important implications for the prevention and treatment of heart disease with aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG031750-03
Application #
8242709
Study Section
Aging Systems and Geriatrics Study Section (ASG)
Program Officer
Kohanski, Ronald A
Project Start
2010-04-15
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
3
Fiscal Year
2012
Total Cost
$411,291
Indirect Cost
$139,093
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Collin, Julia; Gössl, Mario; Matsuo, Yoshiki et al. (2015) Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. Int J Cardiol 181:57-64
Matsuzawa, Yasushi; Li, Jing; Aoki, Tatsuo et al. (2015) Predictive value of endothelial function by noninvasive peripheral arterial tonometry for coronary artery disease. Coron Artery Dis 26:231-8
Matsuzawa, Yasushi; Guddeti, Raviteja R; Kwon, Taek-Geun et al. (2015) Treating coronary disease and the impact of endothelial dysfunction. Prog Cardiovasc Dis 57:431-42
Yoshino, Satoshi; Cassar, Andrew; Matsuo, Yoshiki et al. (2014) Fractional flow reserve with dobutamine challenge and coronary microvascular endothelial dysfunction in symptomatic myocardial bridging. Circ J 78:685-92
Gössl, Mario; Yoon, Myeong-Ho; Choi, Byoung-Jwoo et al. (2014) Accelerated coronary plaque progression and endothelial dysfunction: serial volumetric evaluation by IVUS. JACC Cardiovasc Imaging 7:103-4
Khangura, Kirandeep K; Eirin, Alfonso; Kane, Garvan C et al. (2014) Cardiac function in renovascular hypertensive patients with and without renal dysfunction. Am J Hypertens 27:445-53
Matsuzawa, Yasushi; Lerman, Amir (2014) Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis 25:713-24
Yoshino, Satoshi; Cilluffo, Rebecca; Best, Patricia J M et al. (2014) Single nucleotide polymorphisms associated with abnormal coronary microvascular function. Coron Artery Dis 25:281-9
Khangura, Kirandeep K; Eirin, Alfonso; Kane, Garvan C et al. (2014) Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension. J Hypertens 32:1300-6
Chen, Zhi; Herrmann, Sandra M S; Zhu, Xiangyang et al. (2014) Preserved function of late-outgrowth endothelial cells in medically treated hypertensive patients under well-controlled conditions. Hypertension 64:808-14

Showing the most recent 10 out of 25 publications